Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Human Rabies Immunoglobulin (IM) market report explains the definition, types, applications, major countries, and major players of the Human Rabies Immunoglobulin (IM) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Weiguang Bio
Grifols
Bharat Serum
Sanofi
Shuanglin Bio
VINS
CBPO
CNBG
Kamada
CSL Behring
Shanghai RAAS
Sichuan Yuanda Shuyang
By Type:
ERIG
HRIG
By End-User:
Category II Exposure
Category III Exposure
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Human Rabies Immunoglobulin (IM) Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Human Rabies Immunoglobulin (IM) Outlook to 2028- Original Forecasts
-
2.2 Human Rabies Immunoglobulin (IM) Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Human Rabies Immunoglobulin (IM) Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Human Rabies Immunoglobulin (IM) Market- Recent Developments
-
6.1 Human Rabies Immunoglobulin (IM) Market News and Developments
-
6.2 Human Rabies Immunoglobulin (IM) Market Deals Landscape
7 Human Rabies Immunoglobulin (IM) Raw Materials and Cost Structure Analysis
-
7.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
-
7.2 Human Rabies Immunoglobulin (IM) Price Trend of Key Raw Materials
-
7.3 Human Rabies Immunoglobulin (IM) Key Suppliers of Raw Materials
-
7.4 Human Rabies Immunoglobulin (IM) Market Concentration Rate of Raw Materials
-
7.5 Human Rabies Immunoglobulin (IM) Cost Structure Analysis
-
7.5.1 Human Rabies Immunoglobulin (IM) Raw Materials Analysis
-
7.5.2 Human Rabies Immunoglobulin (IM) Labor Cost Analysis
-
7.5.3 Human Rabies Immunoglobulin (IM) Manufacturing Expenses Analysis
8 Global Human Rabies Immunoglobulin (IM) Import and Export Analysis (Top 10 Countries)
-
8.1 Global Human Rabies Immunoglobulin (IM) Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Human Rabies Immunoglobulin (IM) Export by Region (Top 10 Countries) (2017-2028)
9 Global Human Rabies Immunoglobulin (IM) Market Outlook by Types and Applications to 2022
-
9.1 Global Human Rabies Immunoglobulin (IM) Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global ERIG Consumption and Growth Rate (2017-2022)
-
9.1.2 Global HRIG Consumption and Growth Rate (2017-2022)
-
9.2 Global Human Rabies Immunoglobulin (IM) Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Category II Exposure Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Category III Exposure Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Human Rabies Immunoglobulin (IM) Market Analysis and Outlook till 2022
-
10.1 Global Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.2.2 Canada Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.2.3 Mexico Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.2 UK Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.3 Spain Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.4 Belgium Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.5 France Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.6 Italy Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.7 Denmark Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.8 Finland Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.9 Norway Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.10 Sweden Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.11 Poland Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.12 Russia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.3.13 Turkey Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.2 Japan Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.3 India Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.4 South Korea Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.5 Pakistan Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.6 Bangladesh Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.7 Indonesia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.8 Thailand Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.9 Singapore Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.10 Malaysia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.11 Philippines Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.4.12 Vietnam Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.2 Colombia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.3 Chile Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.4 Argentina Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.5 Venezuela Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.6 Peru Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.7 Puerto Rico Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.5.8 Ecuador Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6.2 Kuwait Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6.3 Oman Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6.4 Qatar Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6.5 Saudi Arabia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.6.6 United Arab Emirates Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.7.2 South Africa Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.7.3 Egypt Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.7.4 Algeria Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
-
10.8.2 New Zealand Human Rabies Immunoglobulin (IM) Consumption (2017-2022)
11 Global Human Rabies Immunoglobulin (IM) Competitive Analysis
-
11.1 Weiguang Bio
-
11.1.1 Weiguang Bio Company Details
-
11.1.2 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.1.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Grifols
-
11.2.1 Grifols Company Details
-
11.2.2 Grifols Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Grifols Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Bharat Serum
-
11.3.1 Bharat Serum Company Details
-
11.3.2 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Bharat Serum Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.3.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Sanofi
-
11.4.1 Sanofi Company Details
-
11.4.2 Sanofi Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Sanofi Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.4.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Shuanglin Bio
-
11.5.1 Shuanglin Bio Company Details
-
11.5.2 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.5.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 VINS
-
11.6.1 VINS Company Details
-
11.6.2 VINS Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 VINS Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.6.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 CBPO
-
11.7.1 CBPO Company Details
-
11.7.2 CBPO Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 CBPO Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 CNBG
-
11.8.1 CNBG Company Details
-
11.8.2 CNBG Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 CNBG Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.8.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Kamada
-
11.9.1 Kamada Company Details
-
11.9.2 Kamada Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Kamada Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.9.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 CSL Behring
-
11.10.1 CSL Behring Company Details
-
11.10.2 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 CSL Behring Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.10.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Shanghai RAAS
-
11.11.1 Shanghai RAAS Company Details
-
11.11.2 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.11.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Sichuan Yuanda Shuyang
-
11.12.1 Sichuan Yuanda Shuyang Company Details
-
11.12.2 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
11.12.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
-
11.12.5 Recent Research and Development Strategies
12 Global Human Rabies Immunoglobulin (IM) Market Outlook by Types and Applications to 2028
-
12.1 Global Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global ERIG Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global HRIG Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Category II Exposure Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Category III Exposure Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Human Rabies Immunoglobulin (IM) Market Analysis and Outlook to 2028
-
13.1 Global Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.2.2 Canada Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.2.3 Mexico Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.2 UK Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.3 Spain Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.4 Belgium Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.5 France Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.6 Italy Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.7 Denmark Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.8 Finland Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.9 Norway Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.10 Sweden Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.11 Poland Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.12 Russia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.3.13 Turkey Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.2 Japan Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.3 India Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.4 South Korea Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.8 Thailand Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.9 Singapore Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.11 Philippines Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.2 Colombia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.3 Chile Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.4 Argentina Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.6 Peru Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6.3 Oman Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6.4 Qatar Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.7.2 South Africa Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.7.3 Egypt Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.7.4 Algeria Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Human Rabies Immunoglobulin (IM) Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Human Rabies Immunoglobulin (IM)
-
Figure of Human Rabies Immunoglobulin (IM) Picture
-
Table Global Human Rabies Immunoglobulin (IM) Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Human Rabies Immunoglobulin (IM) Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global ERIG Consumption and Growth Rate (2017-2022)
-
Figure Global HRIG Consumption and Growth Rate (2017-2022)
-
Figure Global Category II Exposure Consumption and Growth Rate (2017-2022)
-
Figure Global Category III Exposure Consumption and Growth Rate (2017-2022)
-
Figure Global Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Table North America Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure United States Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Canada Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Mexico Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table Europe Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure Germany Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure UK Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Spain Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Belgium Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure France Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Italy Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Denmark Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Finland Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Norway Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Sweden Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Poland Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Russia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Turkey Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table APAC Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure China Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Japan Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure India Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure South Korea Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Thailand Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Singapore Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Philippines Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table South America Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure Brazil Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Colombia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Chile Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Argentina Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Peru Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table GCC Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure Bahrain Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Oman Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Qatar Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table Africa Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure Nigeria Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure South Africa Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Egypt Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure Algeria Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table Oceania Human Rabies Immunoglobulin (IM) Consumption by Country (2017-2022)
-
Figure Australia Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Human Rabies Immunoglobulin (IM) Consumption and Growth Rate (2017-2022)
-
Table Weiguang Bio Company Details
-
Table Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Weiguang Bio Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Grifols Company Details
-
Table Grifols Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Grifols Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Bharat Serum Company Details
-
Table Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bharat Serum Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Shuanglin Bio Company Details
-
Table Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shuanglin Bio Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table VINS Company Details
-
Table VINS Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table VINS Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table VINS Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table CBPO Company Details
-
Table CBPO Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table CBPO Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table CNBG Company Details
-
Table CNBG Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table CNBG Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Kamada Company Details
-
Table Kamada Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kamada Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table CSL Behring Company Details
-
Table CSL Behring Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table CSL Behring Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Shanghai RAAS Company Details
-
Table Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shanghai RAAS Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
-
Table Sichuan Yuanda Shuyang Company Details
-
Table Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Main Business and Markets Served
-
Table Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
-
Figure Global ERIG Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global HRIG Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Category II Exposure Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Category III Exposure Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Table North America Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure United States Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure Germany Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure China Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure Brazil Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Human Rabies Immunoglobulin (IM) Consumption Forecast by Country (2022-2028)
-
Figure Australia Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Human Rabies Immunoglobulin (IM) Consumption Forecast and Growth Rate (2022-2028)
-
